Literature DB >> 30414063

The burden of cancer in Spain.

X Badía1, M Tort2, A-G Manganelli1,3, C Camps4,5, E Díaz-Rubio6,7.   

Abstract

INTRODUCTION: Cancer imposes a huge financial burden in all developed countries. This study estimates the burden of cancer in Spain in 2015.
METHODS: The most recent available epidemiological data on prevalence, incidence and mortality, and the economic data on direct (hospital, drugs, and primary care) and indirect (productivity) costs was used from the social perspective.
RESULTS: Prevalence, incidence, and mortality were, respectively, 1240, 478, and 218 per 100,000 inhabitants. Mortality was higher for men, while disability rates were higher for women. Direct costs accounted for 4818 million euros and indirect costs were 640 million euros in 2015. Direct costs were almost completely borne by the hospital (94%). Total burden of cancer in Spain was 5458 million euros in 2015.
CONCLUSIONS: In Spain, the costs of cancer were mainly borne by the hospital and these costs might increase in the future due to the expected increase in longevity. Further research would be needed to investigate whether it is possible to redistribute the economic burden of cancer.

Entities:  

Keywords:  Burden of disease; Cancer; Cost of illness; Oncology

Year:  2018        PMID: 30414063     DOI: 10.1007/s12094-018-1972-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  2 in total

1.  Economic Burden of Malignant Tumors - Yichang City, Hubei Province, China, 2019.

Authors:  Xiaojuan Long; Fangfang Lu; Xianglong Xiang; Jiajuan Yang; Chengzhong Xu; Pei Zhang; Shicheng Yu; Qiqi Wang; Chi Hu
Journal:  China CDC Wkly       Date:  2022-04-15

2.  A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application.

Authors:  Sebastián García-Sánchez; Roberto Collado-Borrell; Eva González-Haba; José Luis Revuelta-Herrero; Vicente Escudero-Vilaplana; María Belén Marzal-Alfaro; María Norberta Sánchez-Fresneda; Ana Mur-Mur; Ana Herranz; Miguel Martín; María Sanjurjo
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.